Vanta Bioscience Limited Share Price

Equities

VANTABIO6

INE695X01011

Biotechnology & Medical Research

Market Closed - Bombay S.E. 11:00:51 30/04/2024 BST 5-day change 1st Jan Change
69.45 INR +4.99% Intraday chart for Vanta Bioscience Limited +15.19% +29.69%

Financials

Sales 2022 100M 1.2M 96.19M Sales 2023 68.95M 826K 66.2M Capitalization 363M 4.35M 348M
Net income 2022 - 0 0 Net income 2023 -64M -767K -61.45M EV / Sales 2022 11.4 x
Net Debt 2022 446M 5.35M 429M Net Debt 2023 571M 6.84M 548M EV / Sales 2023 13.5 x
P/E ratio 2022
786 x
P/E ratio 2023
-5.6 x
Employees 47
Yield 2022 *
-
Yield 2023
-
Free-Float 28.14%
More Fundamentals * Assessed data
Dynamic Chart
Vanta Bioscience Bags INR12 Million Order to Conduct Technical Studies MT
Vanta Bioscience Limited Receives an Order of INR 12 Million from A Large Indian Multinational Company CI
Vanta Bioscience Limited Appoints Sangeetha Padam as Company Secretary and Compliance Officer CI
Vanta Bioscience Bags INR5.7 Million Order for Good Laboratory Practices Studies MT
Vanta Bioscience Limited Receives Order of INR 5.7 Million from Singapore Company to Carry Out GLP Studies CI
Vanta Bioscience Limited Approves the Change in Designation of Vyasmurti Madhavrao Shingatgeri from Whole Time Director to Non-Executive Director CI
Vanta Bioscience Limited Reports Earnings Results for the Half Year Ended September 30, 2023 CI
Vanta Bioscience Limited Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Vanta Bioscience Limited Announces Resignation of Vidisha Rathod as Company Secretary and Compliance Officer CI
Vanta Bioscience Limited Appoints Vidisha Rathod as Company Secretary and Compliance Officer CI
Vanta Bioscience Limited Announces Resignation of Zoheb S Sayani as Company Secretary / Compliance Officer CI
Vanta Bioscience Limited Reports Earnings Results for the Full Year Ended March 31, 2022 CI
Vanta Bioscience to Conduct Animal and Agrochem Studies for Coromandel International MT
Vanta Bioscience Limited Receives Order of INR 11.8 Million from Coromandel International Limited CI
Vanta Bioscience Limited Announces CFO Changes CI
More news
1 day+4.99%
1 week+15.19%
Current month+8.52%
1 month+8.52%
3 months+19.74%
6 months+66.15%
Current year+29.69%
More quotes
1 week
59.00
Extreme 59
69.45
1 month
59.00
Extreme 59
69.45
Current year
54.00
Extreme 54
101.64
1 year
37.00
Extreme 37
101.64
3 years
37.00
Extreme 37
190.00
5 years
37.00
Extreme 37
195.50
10 years
37.00
Extreme 37
195.50
More quotes
Managers TitleAgeSince
Chief Executive Officer 37 28/04/16
Director of Finance/CFO - 10/11/21
Chief Tech/Sci/R&D Officer 64 03/01/17
Members of the board TitleAgeSince
Chairman 64 28/04/16
Chief Executive Officer 37 28/04/16
Chief Tech/Sci/R&D Officer 64 03/01/17
More insiders
Date Price Change Volume
30/04/24 69.45 +4.99% 5,250
29/04/24 66.15 +5.00% 4,500
26/04/24 63 +2.42% 5,250
24/04/24 61.51 -2.83% 7,500
23/04/24 63.3 +4.99% 3,750

Delayed Quote Bombay S.E., April 30, 2024 at 11:00 am

More quotes
Vanta Bioscience Limited is an India-based preclinical contract research company. The Company is providing services of testing and contract research in the fields of clinical research, pre-clinical research, biopharma services, analytical testing and research and environmental studies. It offers a host of preclinical safety assessment services for clientele from pharmaceutical, medical devices, nutraceuticals, feed additive, biotech, agrochemicals, cosmetics, and chemical industries. In addition, it also provides risk assessment services for evaluating the safety of the active pharmaceutical ingredients (API), excipients, extractable and leachable, including pharmaceutical impurities resulting due to manufacturing process or due to degradation of the product. It also provides services for determination of health-based exposure limits, such as permitted daily exposure (PDE) or allowable daily exposure (ADE), including occupational exposure limits (OEL) for pharmaceutical manufacturers.
More about the company
  1. Stock Market
  2. Equities
  3. VANTABIO6 Stock